Argininosucciniclyase deficiency (ASLD) has been shown by the UCDC to have unique characteristics in clinical and physiologic behavior from the other urea cycle disorders. Accounting for around 15-20% of UCD disorders, ASLD patients have relatively worse cognitive outcomes, hepatic disorders, and vascular problems than other UCDs. Work by consortium members has clearly demonstrated a tissue and molecular specific role for ASL in the generation of nitric oxide (NO). As part of a substrate channeling complex involving ASS, ASL, and eNOS, we have shown that cells with defective ASL lose the ability to generate sufficient NO. This implies both a kinetic and structural role for the enzyme in NO production. This proposal will address the effect of bypassing this complex using a synthetic NO donor. We have also shown that in a hypertensive symptomatic patient that improvement in hypertension occurred and trends toward cognitive improvement occurred with NO donor treatment. Before this treatment would be accepted for widespread use in ASLD or other UCD patients an in depth double-blind placebo-controlled crossover study needs to be conducted. This proposed study will phenotype these patients in depth and study vaso-regulation on and off therapy as well as neurocognitive effects. If successful this would lead to a new tool for the treatment of patients with UCDs addressing some of the comorbidities identified by the UCDC longitudinal study and consortium members.
This study seeks to correct a biochemical derangement in UCD which was previously unrecognized. It provides evidence of NO deficiency in ASLD and uses a novel therapy to correct the abnormality and hopefully ameliorate hypertension and cognitive deficits resulting from a distal block in the urea cycle. The approach of NO deficiency may be relevant to more common disorders.
|Kho, Jordan; Tian, Xiaoyu; Wong, Wing-Tak et al. (2018) Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. Am J Hum Genet 103:276-287|
|Posset, Roland; Garbade, Sven F; Boy, Nikolas et al. (2018) Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-a successful strategy for clinical research of rare diseases. J Inherit Metab Dis :|
|Nagamani, Sandesh C S; Agarwal, Umang; Tam, Allison et al. (2018) A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers. Genet Med 20:708-716|
|Sin, Yuan Yan; Ballantyne, Laurel L; Richmond, Christopher R et al. (2018) Transplantation of Gene-Edited Hepatocyte-like Cells Modestly Improves Survival of Arginase-1-Deficient Mice. Mol Ther Nucleic Acids 10:122-130|
|Uittenbogaard, Martine; Brantner, Christine A; Chiaramello, Anne (2018) Epigenetic modifiers promote mitochondrial biogenesis and oxidative metabolism leading to enhanced differentiation of neuroprogenitor cells. Cell Death Dis 9:360|
|Uittenbogaard, Martine; Brantner, Christine A; Fang, ZiShui et al. (2018) Novel insights into the functional metabolic impact of an apparent de novo m.8993T>G variant in the MT-ATP6 gene associated with maternally inherited form of Leigh Syndrome. Mol Genet Metab 124:71-81|
|Waisbren, Susan E; Cuthbertson, David; Burgard, Peter et al. (2018) Biochemical markers and neuropsychological functioning in distal urea cycle disorders. J Inherit Metab Dis 41:657-667|
|Sin, Yuan Yan; Price, Phillipe R; Ballantyne, Laurel L et al. (2017) Proof-of-Concept Gene Editing for the Murine Model of Inducible Arginase-1 Deficiency. Sci Rep 7:2585|
|Shapiro, Elsa; Bernstein, Jessica; Adams, Heather R et al. (2016) Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Mol Genet Metab 118:65-9|
|Opladen, Thomas; Lindner, Martin; Das, Anibh M et al. (2016) In vivo monitoring of urea cycle activity with (13)C-acetate as a tracer of ureagenesis. Mol Genet Metab 117:19-26|
Showing the most recent 10 out of 113 publications